As a central research infrastructure on the Lübeck campus, the ICB-L supports numerous projects and studies in the collection, preparation, and storage of biospecimens and is itself part of numerous collaborations and networks. A current selection can be found here:
German Biobank Network (GBN)
Under the umbrella of the German Biobank Node (GBN), academic biobanks at 36 locations and an IT development center have joined forces in the German Biobank Network (GBN). The GBN biobanks establish joint quality standards and make their human biospecimens and associated data available to medical research throughout Europe.
GBN is also a partner in the European biobank network BBMRI-ERIC, which focuses on networking and exchange of experience between biobanks within Europe.
Further information can be found at www.bbmri.de
University Cancer Center Schleswig-Holstein (UCCSH)
The UCCSH is the association of all oncology facilities of the University Medical Center Schleswig-Holstein, with locations in Kiel and Lübeck, supported by the Christian-Albrechts-University of Kiel and the University of Lübeck.
As a leading supra-regional cancer center in Schleswig-Holstein and beyond, it offers patients with oncological diseases interdisciplinary care at the highest level, incorporating the latest research findings and the opportunity to participate in clinical trials of all development phases.
A particular concern of the UCCSH is to optimize the connection between clinical research and basic research and thus make new approaches in cancer therapy quickly available to patients. The UCCSH provides integrated, interdisciplinary systems medicine and data management according to international standards for this purpose. Further information about the UCCSH can be found here: https://www.uksh.de/uccsh
In addition, oncology at the UKSH is certified by the German Cancer Society (DKG) as a “Center for Personalized Medicine (ZPM-O)”. As a member of the German Center for Personalized Medicine (DNPM), the ZPM-O of the UKSH is committed to improving the care and quality of life of people with rare or advanced tumor diseases through new diagnostic procedures and targeted therapies: Center for Personalized Medicine – Oncology at UKSH (ZPM-O).
The heart of the center is the Molecular Tumor Board (MTB): Molecular Tumor Board (MTB)
With its infrastructure, the ICB-L supports the UCCSH in the area of biobanking logistics of the Molecular Tumor Board as well as in sample collection as part of liquid biopsy research projects and cohorts, among others of the European Liquid Biopsy Society (ELBS) or the DKTK Joint Funding (e.g. EXLIQUID).
Contact UKSH, Campus Lübeck
Executive Board UCCSH:
Prof. Dr. med. Nikolas von Bubnoff, Director, Department of Hematology and Oncology
Coordination Molecular Tumor Board (UCCSH) & Scientific Director ZPM-O:
Dr. rer. nat. Stephanie Fliedner
OUTLIVE-CRC
The ICB-L is involved in the research network “OUTLIVE-CRC” to improve the prognosis and quality of life of young colorectal cancer patients. The measure “Funding of research networks for the prevention of colorectal cancer in younger and future generations” funded by the Federal Ministry of Research, Technology and Space (BMFTR) aims to achieve rapid progress in researching causes, promoting health, early detection and follow-up care for young people with colorectal cancer.
From stool and blood samples of affected individuals, information on intestinal metabolism, the gut microbiome and further molecular levels is to be collected and analyzed using artificial intelligence. The interdisciplinary research network “OUTLIVE-CRC” aims to identify biomarkers that indicate early stages of cancer. The influence of personalized nutrition is also to be investigated. A special feature of the network is the continuous involvement of patients in order to tailor research closely to the needs of those affected and their relatives.
Further information can be found at https://www.outlive-crc.uni-luebeck.de/konsortium
Project leads:
Prof. Dr. Stefanie Derer-Petersen, Institute of Nutritional Medicine, UKSH Campus Lübeck
Prof. Dr. Nikolas von Bubnoff, Department of Hematology and Oncology, UKSH Campus Lübeck
PANTAU
The Collaborative Research Center (CRC) 1526 “Pathomechanisms of Antibody-Mediated Autoimmune Diseases (PANTAU): Insights from Pemphigoid Diseases” investigates the development of antibody-mediated autoimmune diseases with the aim of developing new strategies for diagnosing and treating these diseases.
Further information on the background to the research as well as the goals, projects and members of CRC 1526 can be found at: https://www.sfb1526.uni-luebeck.de/
The ICB-L is partially responsible for the quality-assured preparation and storage of the biospecimens collected as part of the CRC.
Head:
Prof. Dr. Christian Sadik, Department of Dermatology, Allergology and Venereology, UKSH Campus Lübeck
Sexdiversity
The Collaborative Research Center (CRC) 1665 “Sex diversity” investigates the diverse manifestations of physical sex in various contexts. Led by the University of Lübeck, the consortium brings together 27 researchers from medicine, biology, neuroscience, humanities, and social sciences in 17 subprojects. The research also involves the University Medical Center Schleswig-Holstein and the Christian-Albrechts-University of Kiel, as well as selected external experts from Berlin, Flensburg, Magdeburg, Munich, and Hanover.
The biospecimens collected as part of the CRC1665 are prepared and stored, among others, in the ICB-L.
Further information can be found at: https://www.sfb1665.uni-luebeck.de/sfb-1665
Spokesperson:
Prof. Dr. Olaf Hiort, Department of Pediatrics and Adolescent Medicine, UKSH Campus Lübeck
Co-spokesperson:
Prof. Dr. Christoph Rehmann-Sutter, Institute for the History of Medicine and Science Studies, University of Lübeck
NeoTreme
The phase II study on preoperative gemcitabine plus cisplatin in combination with durvalumab (MEDI4736) and tremelimumab in patients with intrahepatic cholangiocarcinoma (NeoTreme) examines the potential of an innovative treatment strategy with the involvement of five trial centers. The study is organizationally supported by the University Cancer Center Schleswig-Holstein (UCCSH). Further information on the study can be found at: Innovative therapeutic approach for cancer of the bile duct
The ICB-L is responsible for the quality-assured storage of the biospecimens collected in the NeoTreme study.
Study leads:
Prof. Dr. Jens Marquardt, Department of Medicine I, UKSH Campus Lübeck
PD Dr. med. Carolin Zimpel, Department of Medicine I, UKSH Campus Lübeck
Project coordinator
Dr. Christina Schwitlick, University Cancer Center Schleswig-Holstein
